I. ANTIOVULATORY STEROIDS
In 1956 Pincus and associates (1, 2) reported that 17a-ethyl-19-nortestosterone (nor ethandrolone), 17a-ethynyl-l9-nortestosterone (norethindrone), and 17a-ethynyl-5(10)-estrenol one (norethynodrel) inhibit ovulation in the rabbit. They also observed that these com pounds had progestational activity and an antifertility effect in rats.
It will be noted that these steroids are in two distinct chemical classifications : nor ethandrolone and norethindrone are derivatives of nortestosterone, whereas norethynodrel, having a 5(10) double bond, is not a nortestosterone ( Fig. 1) . A study of the endocrine properties of such compounds also showed a differentiation of biological properties related to chemical structure.
For example, the derivatives of 19-nortestosterone all have some degree of androgenic activity, whereas norethynodrel is completely devoid of such an action (Table 1 ). The 19-nortestosterones are also anabolic and antiestrogenic. In contrast, nor ethynodrel is neither anabolic nor antiestrogenic and in fact possesses some estrogenic activity. Based on such properties norethynodrel, synthesized by Dr. Frank Colton of our laboratories, was selected for detailed experimental and clinical evaluation. The results of these studies, performed by many investigators, will be summarized. The results obtained in these tests with several steroid analogues are summarized in Table 2 . It will be noted that all of the compounds are rated as active in the Clauberg test following either subcutaneous or oral administration (5) (6) (7) (8) Estrogenicity. Estrogenic activity may be determined by measuring the increase in uterine weight produced in immature female mice. The vaginal smear response in castrated adult female rats was also employed (5), as this method is more specific for estrogenic activity than the uterine weight method. It is particularly important that completely pure samples of steroids be used for determination of estrogenicity as a small amount of contaminating steroid may give a positive response (5).
Derivatives of nortestosterone produced a slight increase in uterine weight (Table 3 ).
This effect, observed at high dose levels, is characteristic of a progestin and does not indicate estrogenicity.
In the vaginal smear test in rats, a selective test for estrogenicity, these compounds are inactive. Norethynodrel, on the other hand, has estrogenicity equi valent to 5 to 7 percent the potency of estrone in both tests. Such activity was obtained with pure compound after exhaustive recrystallization and chromatography and is not due to any impurity. Thus, norethynodrel is the first steroid to possess both progestational and estrogenic activity in the same molecule. Androgenic activity. The androgenicity of a group of steroids was measured by the increase in ventral prostate and seminal vesicle weight produced in castrated rats. Com pounds in the nortestosterone series are less potent than testosterone, but nevertheless possess some androgenicity (8) . Norethynodrel is completely devoid of androgenic activity in these tests and the experimental findings are corroborated by clinical data. Clinically 17-methyl-19-nortestosterone is the most androgenic of the group and produces androgenic side effects in women (9). 17-Ethyl-19-nortestosterone is devoid of androgenic effects at doses of 20 to 30 mg per day. Minimal androgenicity may be observed in some patients at doses of 50 mg per day, the effect becoming greater at doses of 75 or 100 mg per day. 17-Ethynyl-19-nortestosterone may also produce androgenic side effects (10) . The estrenol one compound, norethynodrel, employed clinically as Enovid, does not produce any signs of androgenicity in women, even when administered in high doses over a long period of time in the treatment of endometriosis (11, 12) . 4 Myotropic activity. Myotropic activity was determined by the increase produced in the weight of the levator ani muscle of castrated male rats (5). The nortestosterone deriva tives can be quite potent in this test, whereas norethynodrel is inactive in this respect (Table 3) . Myotropic activity is independent of progestational potency. Maintenance of pregnancy. When pregnant rats or rabbits are ovariectomized on the eighth and twelfth days of pregnancy respectively, the fetus will be resorbed. Injections of progesterone will maintain pregnancy. When some of the newer, more potent, pro gestational compounds were studied in this regard, it was observed that not all of them maintain pregnancy (Table 4) types of studies. Antiestrogenic activity. An antiestrogenic compound will block the increase in uterine weight produced by estrone. All of the 17-alkyl derivatives of 19-nortestosterone which we have studied possess antiestrogenic activity. Based on the minimal androgenic potency of the compounds, they are much more potent than testosterone as antiestrogens (Table   1 ). Thus, the antiestrogenic effect of these compounds appears to be an independent property of the molecules. Conversely, norethynodrel is not antiestrogenic (14) . Pituitary inhibition. Saunders (5) has studied the effect of norethynodrel on pituitary gonadotrophins. Donor rats received 1 mg of steroid daily for five days. The pituitary gland was then removed, homogenized, and injected into test rats over a period of three days. The pituitary gland from untreated control animals produces a marked increase in ovarian weight in the test rats. The pituitary from norethynodrel-treated rats produced only a slight increase in ovarian weight, demonstrating a pituitary inhibition.
Epstein, Kupperman and Cutler (10) Edgren compared the properties of norethynodrel and 17a-ethynyl-l9-nortestosterone (14) . When injected into mice and uterine weight-response determined, he found that nor ethynodrel produces a steep dose-response curve characteristic of an estrogen, whereas 17a ethynyl-19-nortestosterone produces the shallow dose-response curve of a progestin. When administered orally, each compound produces its characteristic response curve demonstrat ing that oral administration is not followed by the metabolism of one compound to the other. Further, as discussed above under antiestrogenicity, the 17-nortestosterones are antiestrogenic, whereas norethynodrel, administered parenterally or orally under the same conditions, does not produce a similar response. Lastly, the 19-nortestosterones may pro duce androgenicity in some patients, whereas this has not been observed following the administration of norethynodrel for prolonged periods of time. These facts demonstrate that biologically norethynodrel is a distinct entity. Summary of endocrine properties. As summarized in Table 1 , norethynodrel is a steroid that has progestational, estrogenic and pituitary inhibiting properties. It is devoid of androgenic, anabolic and antiestrogenic effects.
III. ANTIFERTILITY EFFECTS OF NORETHYNODREL : EXPERIMENTAL RESULTS
It was first reported by Pincus and associates (1, 2) After 35 days of the recovery period , ovarian weight of the norethynodrel-treated animals had returned to the normal control range. During the recovery the treated animals became pregnant and in most treated groups the percent pregnancy approached that of the control group. Recovery was complete in the norethynodrel-treated rats (Fig . 5) .
Following the demonstration of effectiveness of norethynodrel in animals , observations were made in women by Rock, Garcia, and Pincus (15) (16) (17) . These authors, employing basal temperature, vaginal smears, and pregnanediol excretion as a measure of ovulation , found that norethynodrel will inhibit ovulation in succeeding menstrual cycles . This finding was significant, for although the standard estrogens will inhibit ovulation during the first cycle, they usually will not do so in the following cycle . Rock and associates also noted that spotting may occur in such subjects during the administration of nor ethynodrel so that they added 1.5% of an estrogen, 3-methyl ether of ethynylestradiol , to limit this factor. Norethynodrel with 1.5% of this added estrogen constitutes Enovid . Following this demonstration of effectiveness Enovid was then subjected to a wide evaluation as a practical means of family planning and the studies performed by various investigators are summarized.
IV. ANTIFERTILITY EFFECTS OF ENOVID : CLINICAL RESULTS
Dosage of Enovid. In the following studies, Enovid was administered cyclically as follows : 1 tablet per day was given for 20 days beginning on the fifth day of the menstrual cycle (medication should begin on the fifth day whether or not menstrual flow has ceased). Thus, the patients receive a tablet of Enovid from the fifth to the twenty fourth day of the cycle. Following discontinuance of therapy on the twenty-fifth day, bleeding began on the average three days later. The patients were instructed to again count the first day of bleeding as the first day of a new cycle and to restart daily tablet of Enovid on the fifth day. Thus, each patient took 20 tablets of Enovid per month throughout the period of study.
Measurement of effectiveness. Tietze (18) has discussed and defined three measures of the effectiveness of contraceptive methods :
1. Physiological effectiveness: the effectiveness obtained when a given method is used according to instructions on every occasion of need. 2. Clinical effectiveness : the results obtained when a given method is in the hands of users under actual conditions of use. 3. Demographic effectiveness : effectiveness measured by reduction of birth rate of an entire population who have been instructed in a given method and to whom materials are available, whether the individuals are using the method or not. Physiological effectiveness. The data in Table 6 demonstrate that the physiological effectiveness is practically 100 percent. Pincus (19) (see also 20, 21, 22 for other discus sions) did not note any patients becoming pregnant at the 10 mg dose level. Studies were then undertaken employing a 5 mg tablet of Enovid each day for 20 days a month. Tyler (23) (see also 24), employing the 5 mg dose, and Cook and associates (25), using 10 mg or 5 mg doses obtained complete effectiveness. In Pincus' study at the 5 mg dose level one pregnancy was reported during 526 women years of exposure. This one case is listed in the table with a question mark as it could not be definitely established that the patient had taken the tablets as instructed.
Pincus has also carried out studies employing 2.5 mg tablets of Enovid, administered 20 days each month, in a study now encompassing 59 women years of exposure. Even at this dosage level no pregnancy was noted (Table 6 ). Clinical effectiveness. Although the clinical effectiveness of Enovid is very high, it is not 100% as a few patients do not take the tablets as directed. The effect of missing tablets on fertility rate was evaluated by Pincus. As will be noted in Table 7 , when the patient missed from 1 to 5 tablets during the 20 days of administration, 12 pregnancies occurred during 120 calculated years of exposure.
When 6 to 19 tablets were missed during the month, the number of pregnancies increased to 19 pregnancies during 42 years of exposure. Thus, the number of pregnancies increases with the number of tablets missed. Even so, the pregnancy rate is still significantly below the expected level. Cook and associates (25) (Table 8) .
Demographic effectiveness. This topic is beyond the scope of the present paper. However, the studies that have been made indicate the effective ness of family planning.
Withdrawal bleeding. The daily administration of Enovid produces endometrial growth and when medication is stopped a withdrawal bleeding occurs (19, 20, 26) . Such is similar to menstruation in untreated women who have had an anovulatory cycle. As reported by Cook et al. (25) withdrawal bleeding begins 4 to 5 days after stopping the 10 mg tablets and 1 to 2 days after discontinuing the 5 mg tablets.
Approximately one percent of women will not have a withdrawal bleeding after the first month's treatment. It is important, to prevent subsequent pregnancy, that the patient be instructed that when this occurs the next cycle of Enovid treatment should begin one week after the last tablet (day 25) whether or not she has menstruated in the interim.
Spotting or break-through bleeding. The daily administration of Enovid causes growth of the uterine endometrium and in some patients the growth may not be complete enough to completely prevent spotting during the 20 days of treatment. It would appear that a certain balance of progesterone and estrogen is necessary to completely prevent such spotting and the dosage requirements probably vary from patient to patient. In the ex perience of Japanese clinicians the incidence of spotting with Enovid has been about 2 percent. When spotting does occur the patient is instructed to double the dose for several days and then return to the original dose for the remainder of the 20 day course of treat ment. The incidence of spotting is greater during the first cycle of Enovid administra tion and decreases in incidence during subsequent cycles. If spotting continues to occur during the second and third cycles, the patient may be one who requires a higher dosage. Fertility rate following discontinuance of Enovid. Pincus has also studied the pregnancy rate per 100 women years after Enovid therapy was discontinued. During therapy the pregnancy rate, including patients who missed tablets, was 2.25. When Enovid was dis continued and other contraceptive means employed the pregnancy rate rose to 39. In the third group of women, who discontinued Enovid and did not employ other contra ceptive means, the pregnancy rate rose to 210, a normal value ( Table 9 ). Cook and co workers (25) also concluded that Enovid did not inhibit fertility, even after two years of use. In their studies 81% of the patients became pregnant during the first 6 months and the four women who used this method the longest (29-33 months) became pregnant within one month of stopping. The previous use of Enovid was also without effect on the subsequent delivery or complications of pregnancy. Side effects of treatment. The chief side effect oc curring during the use of Enovid is primarily nausea. Many patients state that the nausea resembles that of pregnancy. The incidence of such side effects (Table 10 ) has varied quite widely but dose seem to be highest with the 10 mg dose and approximates 11-15%. The nausea which occurs in certain in dividuals is usually mild and in many patients dis appears after a few days of continued Enovid thera py. The incidence is lower with the 5 mg daily dose of Enovid and lowest with the 2.5 mg dose.
It is difficult to assess a factor such as nausea, particularly in subjects who know they are receiving a new type of treatment for the first time. In another study, Pincus, Rock, and Garcia (20) compared the side effects reported following Enovid administration with those occurring after placebo administra tion. In two of the three groups, admonition was given warning the patients that some nausea may occur. The results, as shown in (19, 20) , and no jaundice has been reported in the extensive clinical studies.
The lack of toxicity of Enovid administered chronically to rats and dogs has been summarized (39).
V. DISCUSSION
Ovulation is normally blocked during pregnancy by endogenous progesterone, thus preventing a superimposed pregnancy. Thus, if one could mimick the hormonal balance present during pregnancy ovulation could be controlled. The oral administration of progesterone can affect ovulation, but daily oral doses of 300 mg are required, and the average cycle is shortened, suggesting that the endometrium is not completely maintained (35) . The attempts of Pincus and associates to find a potent, orally effective substitute for progesterone, has led to finding and exploration of the ovulation-inhibiting effects of Enovid. The biological properties, clinical effectiveness and safety of Enovid have been reviewed in this presentation.
Various studies have attempted to delineate the mechanism of action of this compound. One possible means of action is for Enovid to act directly on the ovary to block the stimulating effect of pituitary gonadotrophins. This was investigated by Saunders (5) . It is known, for example, that Gonadophysin injections markedly increase ovarian weight, and Saunders observed that this effect of Gonadophysin on the ovary was not blocked by norethynodrel. Thus, it does not seem likely that Enovid is inhibiting ovulation by an action at this level. Other data on the pituitary-blocking effects of this compound have been discussed in the first section of the paper. It is probable then that Enovid acts to block ovulation not by affecting ovarian response to gonadotrophins, but by specifically inhibiting the formation or release of pituitary gonadotrophins.
Although the pituitary gonadotrophins may be blocked, thus inhibiting ovulation , Enovid acts directly on the uterus to cause growth of the endometrium. This direct effect on the uterus is due to the progestational and estrogenic effects of this compound . Thus, when treatment is stopped on the 25th day of the cycle , withdrawal bleeding occurs from an anovulatory cycle. The withdrawal bleeding that occurs each month is psychi cally important and indicates further to the subject that she is not pregnant.
Although our discussion has been limited to data relating to ovulation, it should be mentioned that Enovid is effective in many types of menstrual disorders, inadequate luteal phase, and endometriosis.
VI. SUMMARY
Progesterone and other steroids may act to block ovulation. Of the most potent compounds norethynodrel (Enovid) was thought most desirable for detailed evaluation . 
